Hahn Mark W's Form 4 filing
Verona Pharma plc (VRNA) · filed May 1, 2025
- Accession no.
- 0001104659-25-043645
- Filed
- May 1, 2025
- Trade date
- Aug 7, 2024-Apr 29, 2025
- Filing delay
- 267 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $811.4K. It was filed 267 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hahn Mark WCIK 0001408502 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 29, 2025 | Ordinary Shares | MOption exerciseAcquired | +229,512 | $0.00 | $0 | 13,556,360 | Direct | |
| Apr 29, 2025 | Ordinary Shares | SSaleDisposed | −90,360 | $8.98 | −$811,432.8 | 13,466,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2024 | Ordinary Shares | AGrant or awardAcquired | +1,200,000 | $0.00 | $0 | 1,200,000 | Direct | |
| Apr 29, 2025 | Ordinary Shares | AGrant or awardAcquired | +675,040 | $0.00 | $0 | 675,000 | Direct | |
| Apr 29, 2025 | Ordinary Shares | MOption exerciseDisposed | −229,512 | $0.00 | $0 | 445,488 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.